|Sanofi-Synthelabo Inc. and Aventis Pharmaceuticals Inc., the U.S. pharmaceutical operating entities of the sanofi-aventis Group, are strongly committed to following the voluntary “Guiding Principles” on direct-to-consumer (DTC) advertising developed by the Pharmaceutical Research and Manufacturers of America (PhRMA) and its member companies, including sanofi-aventis.|
“We believe that this approach is the most effective way of addressing the concerns expressed by policymakers and the public about this practice,” said Timothy Rothwell, President and Chief Executive Officer of sanofi-aventis in the United States.
“Overall, DTC advertising has been beneficial to both patients and physicians,” stated Rothwell. “Can we do it better? Yes. And that’s what the guidelines are all about.”
The sanofi-aventis Group is the world’s third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine, and vaccines. The sanofi-aventis Group is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY)
Forward Looking Statements
Sanofi-aventis Group subsidiaries in the United States include Sanofi-Synthelabo Inc., Aventis Pharmaceuticals Inc. and Sanofi Pasteur Inc.
Marc Greene, (212) 551-4400, email@example.com
August 02, 2005